Author

T. M. Grubb

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Approach:experimental assay· 2 Organism:human· 2 Approach:statistical model· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Assay:ChIP-seq· 1 Research Focus:differential expression· 1

Frequent Co-Authors

W. G. Kaelin· 2 shared A. A. Chakraborty· 1 shared A. A. Hakimi· 1 shared A. Chakraborty· 1 shared C. Fraser· 1 shared C. J. Weight· 1 shared C. Salem· 1 shared C. Tang· 1 shared

Activity by Year

2022-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

W. G. Kaelin

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

The SLC1A1/EAAT3 Dicarboxylic Amino Acid Transporter is an Epigenetically Dysregulated Nutrient Carrier that Sustains Oncogenic Metabolic Programs

T. M. Grubb, J. Khatun, S. Matar, F. Ghandour, N. Dubasik, C. Salem, D. A. Orlando, M. G. Guenther, S. R. Martinez, P. Koochaki, J. A. Coker, C. Tang, E. Reznik, R. R. Kotecha, A. A. Hakimi, , A. A. Chakraborty

This study identifies SLC1A1/EAAT3 as an oncogenic transporter in ccRCC driven by H3K27ac, showing its role in sustaining metabolic programs and its potential as a therapeutic target.

bioRxiv · Sep 4, 2023 · PreprintCancer Biology

A Mesenchymal Tumor Cell State Confers Increased Dependency on the BCL-XL Anti-apoptotic Protein in Kidney Cancer

T. M. Grubb, S. Maganti, J. M. Krill-Burger, C. Fraser, L. Stransky, T. Radivoyevitch, K. Sarosiek, F. Vazquez, W. G. Kaelin, A. Chakraborty

The paper identifies a mesenchymal tumor cell state that increases dependency on BCL-XL in kidney cancer, showing anti-tumor efficacy of a BCL-XL inhibitor.

bioRxiv · Jan 29, 2022 · PreprintCancer Biology